Subject: MediSieve is changing the trajectory to tackle COVID-19


  • The Royal Society of Chemistry Interview
  • BioTrinity BioLaunchPad Presentation
  • London Business School Data Analysis Project
  • London and Partners' Business Growth Programme
  • EIT Health Investor Network
  • Meet our employee
Changing the trajectory to tackle COVID-19
The past few months have been challenging for all of us as we try to maintain some semblance of normality through this unprecedented pandemic. At MediSieve, we have been able to continue our work while following developments closely to see how we might be able to do our bit (beyond producing and donating 250 3D printed ear-guards to NHS staff), and have identified that our magnetic blood filtration technology could be used to treat severe COVID-19 patients. Several clinical studies have reported that COVID-19 deaths are caused by overreactions of the immune system similar to those seen in sepsis patients. The products we have been developing for sepsis – which enable the specific removal of harmful cytokines, most importantly IL-6 – could be used to treat these patients and potentially help reduce mortality. Our approach will enable doctors to control the levels of IL-6 in the blood, calming the immune response without leaving patients immunosuppressed so they can still fight the virus. In an attempt to accelerate the development of a reliable and safe treatment and reach the clinic as fast as possible, we have decided to temporarily focus our efforts exclusively on COVID-19. These are trying times, but our team are continuing to work hard on pushing our technology forward while permanently adapting to the changing circumstances. Read on for some of our other updates from the past couple of months.
The Royal Society of Chemistry Case Study
MediSieve was featured in a recent case study by the Royal Society of Chemistry. Our CTO Dr Cristina Blanco-Andujar had a chance to share some insights into the team's contribution to the global fight against COVID-19, including the research expansion and donation of supplies to NHS hospitals.
Read the case study here:

BioTrinity 2020 Presentation
Earlier this month Dr George Frodsham, founder and CEO, gave a BioLaunchPad pitch at BioTrinity 2020. He had a chance to digitally present MediSieve in front of the industry's leading investors and experts. 
Learn more about BioTrinity:

Data Analysis Project with London Business School 
In April MediSieve joined a 10-week data analysis programme run by the London Business School. The objective of the project is to allow students from the Masters in Analytics and Management programme (MAM) to address a live analytical business problem. Two student groups are performing a deep statistical analysis of MediSieve’s data and assisting with the creation of an efficient data assessment tool. The project will provide deeper insights into our data and will help us with future data-driven, efficient experiment planning.
Learn more about MAM Programme:
London & Partners’ Business Growth Programme
MediSieve was recently accepted into the London & Partners’ Business Growth Programme, which will start on 23 June. The free, three-month programme is giving London-based companies the tools to thrive during these challenging times - from mentorship and account management, to expert advice and new business opportunities.
More about the programme
EIT Health Investor Network
Earlier this spring MediSieve was accepted with recommendations to the EIT Health Investor Network, a Europe-wide consortium of investors offering early-stage funding to promising healthcare start-ups. Joining this network will provide us with amazing fundraising opportunities by allowing us to come in to contact with the industry's leaders. 
Learn more:

MediSieve Faces 
MediSieve is working on creating a novel blood filtration technology that will be the first of its kind. But what truly sets us apart from other companies is our people. Meet the individuals who are transforming our dream of eliminating the burden of blood-borne diseases into reality:
Mani Chellappan
Associate Biochemist 
Nationality: British/Indian
Joined: February 2019

What are your responsibilities within MediSieve?
- My responsibilities involve contributing to the sepsis project by testing the ability of our particles to capture bacteria and the different factors that affect it. Additionally I am responsible for data management across the company, this involves setting up processes to ensure that the data is captured properly and ensuring that the valuable data we produce is adequately visualised and converted into actionable insights.

What originally drew you to MediSieve?
- I was drawn to the company because of my desire to apply the knowledge I had gained during both my degrees and MediSieve seemed like the perfect place to do so. I've always wanted my work to help make a real difference in healthcare, and the promise of MediSieve 's technology has been a great source of interest and excitement for me.

What do you like most about working here?
- I think what I like most about working in MediSieve is the culture. It is a great blend of people from diverse backgrounds and you really have freedom to be yourself and explore new ideas.

How did the COVID-19 outbreak affect your personal and work life?
The coronavirus outbreak has definitely meant a change to how we operate at MediSieve, this has involved social distancing and working from home as much as possible. We have had to spread out in the lab and the office to keep working safely so some days have been pretty quiet, and I am looking forward to things going back to normal. On a personal level, it would be great to just see friends and family in person again, virtual drinks are just not the same!

"Imagine a world where doctors are able to target and remove infected cells, pathogens, toxins, or even viruses directly from a patient’s bloodstream."
You may unsubscribe or change your contact details at any time.